J&J Splits: Orthopedics Out, Growth In
Update: 2025-10-14
Description
Johnson & Johnson is spinning off its orthopedics division, DePuy Synthes, to sharpen its focus on faster-growing sectors like oncology and immunology, despite the division bringing in 10% of revenue. Fresh off exceeding Wall Street's expectations and raising its revenue outlook, J&J's stock dipped slightly on the news, but the company is confident this move, led by Namal Nawana, will unlock further growth, though some analysts are wary of the impact of losing a significant revenue stream.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
